Generate:Biomedicines is the latest biotech to benefit from a renewed appetite from investors for publicly listed drug developers. | Generate:Biomedicines is the latest biotech to benefit from a ...
The AI drug discovery specialist is the fifth biotechnology company to go public in February and priced the sector’s largest new stock offering in nearly three years.
Hosted on MSN
Getting In on IPOs Is Getting Easier
Ordinary investors who worry about missing out on a warming initial public offering market should take a deep breath. Their chances of getting shares are improving. Shares in an IPO have long been a ...
My Investing News on MSN
The 10 most successful IPOs of the last decade
Key Points Three nuclear energy companies occupy the top spots with returns ranging from 556.9% to 712.29%. Data center power ...
A SpaceX IPO is not a traditional valuation exercise. It is a bet on unprecedented scale and extreme execution under immense capital intensity. The potential upside is asymmetric, but this relies ...
In 2025, the initial public offering (IPO) market continued to rebound from the 2022 and 2023 slump. For the second year in a row, markets saw more IPOs, more special purpose acquisition companies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results